Ebastine Viatris: Uses, Dosage & Side Effects
A second-generation antihistamine orodispersible tablet for the relief of allergic rhinitis and chronic urticaria in adults and adolescents
Ebastine Viatris is a prescription second-generation antihistamine containing ebastine 10 mg as an orodispersible tablet. It is used for the symptomatic relief of allergic rhinitis (including seasonal and perennial forms) and chronic idiopathic urticaria in adults and adolescents aged 12 years and older. Ebastine works as a prodrug that is rapidly converted in the liver to its pharmacologically active metabolite, carebastine, which selectively blocks peripheral histamine H1 receptors. This prevents histamine from triggering the classic allergic symptoms of sneezing, nasal congestion, rhinorrhea, ocular itching, and skin wheals. The orodispersible formulation dissolves rapidly on the tongue without the need for water, offering convenience for patients who have difficulty swallowing conventional tablets or when water is not readily available.
Quick Facts: Ebastine Viatris
Key Takeaways
- Ebastine Viatris is a second-generation, non-sedating antihistamine used to treat allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives) in adults and adolescents aged 12 years and older.
- The orodispersible tablet dissolves on the tongue without water, providing a convenient option for patients who have difficulty swallowing conventional tablets or when water is unavailable.
- Ebastine is a prodrug metabolized by CYP3A4 in the liver to its active metabolite carebastine, which selectively blocks peripheral H1 histamine receptors with minimal central nervous system sedation.
- Important drug interactions exist with strong CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin) which can increase ebastine plasma levels and potentially cause cardiac effects – concurrent use should be avoided.
- The standard adult dose is 10 mg once daily, taken with or without food. The medication has a long duration of action (elimination half-life of 15–19 hours for carebastine), supporting convenient once-daily dosing.
What Is Ebastine Viatris and What Is It Used For?
Ebastine Viatris contains the active substance ebastine, a second-generation, long-acting histamine H1 receptor antagonist. Unlike first-generation antihistamines such as diphenhydramine, chlorpheniramine, or promethazine, which readily cross the blood-brain barrier and cause significant sedation, ebastine belongs to the newer class of antihistamines that were specifically designed to provide effective antiallergic activity with minimal central nervous system (CNS) effects. This distinction is clinically important because it means patients can manage their allergy symptoms without the drowsiness, impaired concentration, and psychomotor dysfunction associated with older antihistamines.
Ebastine functions as a prodrug. After oral administration, it is rapidly and extensively absorbed from the gastrointestinal tract and undergoes first-pass hepatic metabolism. The liver enzyme cytochrome P450 3A4 (CYP3A4) converts ebastine to its primary active metabolite, carebastine (also known as descarboethoxyloratadine acid analog). It is carebastine, rather than ebastine itself, that is responsible for the therapeutic antihistaminic effect. Carebastine competitively and selectively binds to peripheral histamine H1 receptors, preventing histamine – the principal mediator of immediate allergic reactions – from activating these receptors and triggering the downstream cascade of allergic symptoms.
When allergens such as pollen, dust mites, animal dander, or mold spores enter the body of a sensitized individual, they trigger mast cells and basophils to release histamine. Histamine then binds to H1 receptors located on various tissues, causing the characteristic symptoms of allergic disease: vasodilation and increased vascular permeability (leading to nasal congestion and rhinorrhea), stimulation of sensory nerve endings (causing pruritus and sneezing), smooth muscle contraction (contributing to bronchoconstriction), and increased mucus production. By blocking H1 receptors before histamine can bind, carebastine effectively prevents or reduces these symptoms.
Ebastine Viatris is indicated for two primary conditions:
- Allergic rhinitis (seasonal and perennial): Also commonly known as hay fever (when seasonal), allergic rhinitis affects approximately 10–30% of the global population according to the World Health Organization (WHO). Symptoms include recurrent sneezing, nasal itching, rhinorrhea (runny nose), nasal congestion, and ocular symptoms such as itchy, watery, and red eyes (allergic rhinoconjunctivitis). Seasonal allergic rhinitis is triggered by outdoor allergens such as tree, grass, and weed pollens, while perennial allergic rhinitis is caused by year-round indoor allergens such as house dust mites, pet dander, cockroach allergens, and molds. Clinical studies have demonstrated that ebastine 10 mg once daily significantly reduces total symptom scores for nasal and ocular symptoms compared with placebo, with efficacy comparable to other second-generation antihistamines such as cetirizine and loratadine.
- Chronic idiopathic urticaria (CIU): This condition is characterized by the spontaneous appearance of itchy wheals (hives), angioedema (deep tissue swelling), or both, occurring on most days of the week for six weeks or longer, without an identifiable external trigger. CIU affects approximately 0.5–1% of the population and can significantly impair quality of life. Second-generation H1 antihistamines are recommended as first-line treatment by international guidelines (EAACI/GA2LEN/EDF/WAO). Ebastine 10 mg has been shown to significantly reduce pruritus (itching) intensity, wheal number, and wheal size in patients with chronic urticaria, with improvements maintained over extended treatment periods.
The Ebastine Viatris formulation is specifically designed as an orodispersible tablet, also known as an orally disintegrating tablet (ODT). This formulation uses lyophilization or other rapid-dissolve technology to create a tablet that disintegrates within seconds when placed on the tongue, without the need for water. The active ingredient is then absorbed through the normal gastrointestinal pathway. This dosage form offers several practical advantages: it is convenient for patients who have dysphagia (difficulty swallowing), for elderly patients, for children and adolescents who may resist swallowing conventional tablets, and for situations where water is not readily available (such as during travel or at work). The orodispersible tablet has been shown to have bioequivalent absorption to conventional film-coated ebastine tablets.
After oral administration, ebastine is rapidly absorbed and converted to its active metabolite carebastine. Peak plasma concentrations of carebastine are reached in approximately 2.6 to 4 hours. Carebastine has an elimination half-life of 15 to 19 hours, which supports convenient once-daily dosing. Steady-state plasma levels are typically achieved within 3 to 5 days of repeated daily dosing. The drug is primarily excreted via urine (approximately 66%) as metabolites, with the remainder eliminated in feces.
What Should You Know Before Taking Ebastine Viatris?
Contraindications
Ebastine Viatris must not be used in the following situations:
- Hypersensitivity: Do not take Ebastine Viatris if you are allergic to ebastine or to any of the other ingredients (excipients) in the formulation. If you experience signs of an allergic reaction such as rash, itching, swelling of the face, lips, tongue, or throat, or difficulty breathing after taking the medication, discontinue use immediately and seek medical attention.
- Severe hepatic impairment: Ebastine is extensively metabolized in the liver by CYP3A4. In patients with severe liver disease, the metabolism of ebastine may be significantly impaired, leading to elevated plasma concentrations of the parent drug. Unlike its metabolite carebastine, unmetabolized ebastine has been associated with dose-dependent QT interval prolongation on electrocardiogram (ECG). Therefore, Ebastine Viatris is contraindicated in patients with severe hepatic insufficiency.
Warnings and Precautions
At doses above the recommended 10 mg or when combined with strong CYP3A4 inhibitors, ebastine may cause prolongation of the QT interval on electrocardiogram, which can increase the risk of serious cardiac arrhythmias including torsades de pointes. Do not exceed the recommended dose, and avoid concomitant use with ketoconazole, itraconazole, or erythromycin.
Talk to your doctor or pharmacist before taking Ebastine Viatris if any of the following apply to you:
- Hepatic impairment (mild to moderate): If you have liver disease or reduced liver function, your doctor may need to monitor you more closely. In patients with mild to moderate hepatic impairment, the conversion of ebastine to carebastine may be slower, potentially increasing exposure to the parent compound. Your doctor will assess whether Ebastine Viatris is appropriate for you.
- Cardiac conditions: If you have a history of QT interval prolongation, congenital long QT syndrome, clinically significant bradycardia (slow heart rate), or other cardiac arrhythmias, inform your doctor. Additionally, conditions that predispose to QT prolongation, such as uncorrected hypokalemia (low potassium), hypomagnesemia (low magnesium), or concurrent use of other QT-prolonging medications, require careful assessment before starting ebastine therapy.
- Renal impairment: Although renal impairment does not appear to significantly alter the pharmacokinetics of carebastine, patients with severe renal disease should use Ebastine Viatris with caution and under medical supervision, as there is limited data in this population.
- Elderly patients: Pharmacokinetic studies in elderly healthy volunteers have not shown clinically significant differences compared with younger adults. However, elderly patients are more likely to have concurrent hepatic, renal, or cardiac conditions, and may be taking multiple medications. A careful assessment of the overall clinical picture is warranted before prescribing ebastine to elderly patients.
- Phenylketonuria: Some orodispersible tablet formulations may contain aspartame, a source of phenylalanine. If you have phenylketonuria (PKU), check the excipient list and consult your doctor or pharmacist.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before taking Ebastine Viatris. There are limited data from clinical studies of ebastine use in pregnant women. Animal reproductive toxicity studies have not demonstrated direct or indirect harmful effects on pregnancy, embryonic/fetal development, parturition, or postnatal development at doses corresponding to therapeutic human exposure. However, as a precautionary measure, Ebastine Viatris should preferably not be used during pregnancy unless clearly necessary and the expected benefit to the mother outweighs the potential risk to the fetus.
It is not known whether ebastine or its active metabolite carebastine is excreted in human breast milk. Animal studies have shown that ebastine is excreted in breast milk. A decision must therefore be made whether to discontinue breastfeeding or to discontinue Ebastine Viatris therapy, taking into account the benefit of breastfeeding for the child and the benefit of treatment for the mother. If antihistamine treatment is required during breastfeeding, your doctor may recommend an alternative antihistamine with more established safety data during lactation, such as cetirizine or loratadine.
Driving and Operating Machinery
Ebastine Viatris is classified as a non-sedating antihistamine and is generally not expected to impair the ability to drive or operate machinery at the recommended dose of 10 mg. Clinical studies using psychomotor performance tests have demonstrated that ebastine 10 mg does not significantly impair driving ability, reaction times, or cognitive function compared with placebo. However, individual sensitivity varies, and some patients may experience somnolence (drowsiness) or dizziness. If you notice any effect on your alertness or coordination, you should refrain from driving or operating hazardous machinery until you know how this medication affects you personally.
Children
Ebastine Viatris 10 mg orodispersible tablets are indicated for use in adolescents aged 12 years and older. The safety and efficacy of ebastine in children under 12 years of age have not been established for this particular formulation and strength. For younger children, alternative antihistamine preparations at appropriate pediatric doses may be available and should be discussed with a healthcare provider. Do not give this medicine to children under 12 without specific medical advice.
How Does Ebastine Viatris Interact with Other Drugs?
Because ebastine is primarily metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme system, any drug that strongly inhibits or induces CYP3A4 can alter the plasma concentrations of ebastine and its active metabolite carebastine. This is the principal mechanism through which clinically relevant drug interactions with ebastine occur, and it distinguishes ebastine from some other second-generation antihistamines (such as cetirizine and fexofenadine) that undergo minimal hepatic metabolism.
The clinical significance of CYP3A4 inhibition on ebastine pharmacokinetics has been well characterized in dedicated drug interaction studies. When ebastine is co-administered with potent CYP3A4 inhibitors, the hepatic conversion of ebastine to carebastine is impaired. This leads to a marked increase in plasma concentrations of the parent compound (ebastine) and a modest increase in carebastine levels. The parent compound ebastine, unlike carebastine, has been associated with dose-dependent prolongation of the QT interval on the electrocardiogram, which is the primary safety concern underlying these interactions.
| Interacting Drug | Mechanism | Effect | Clinical Action |
|---|---|---|---|
| Ketoconazole | Strong CYP3A4 inhibitor | Marked increase in ebastine plasma levels; potential QT prolongation | Avoid concurrent use |
| Itraconazole | Strong CYP3A4 inhibitor | Significant increase in ebastine exposure; QT prolongation risk | Avoid concurrent use |
| Erythromycin | Strong CYP3A4 inhibitor | Increased ebastine plasma levels; QT prolongation risk | Avoid concurrent use |
| Clarithromycin | Strong CYP3A4 inhibitor | Increased ebastine plasma levels | Avoid concurrent use; consider alternatives |
| Rifampicin | Strong CYP3A4 inducer | Decreased carebastine plasma levels; reduced efficacy | Monitor therapeutic response; dose adjustment may be needed |
| Grapefruit juice | CYP3A4 inhibitor (intestinal) | Moderate increase in ebastine absorption | Avoid large quantities; take medication with water |
| Other QT-prolonging drugs | Additive pharmacodynamic effect | Increased risk of cardiac arrhythmias | Use with caution; ECG monitoring may be required |
Major Interactions
The most clinically significant drug interactions with Ebastine Viatris involve strong CYP3A4 inhibitors. Pharmacokinetic studies have demonstrated that co-administration of ebastine with ketoconazole (a potent azole antifungal) increased the mean area under the curve (AUC) of ebastine by approximately 16-fold and the peak plasma concentration (Cmax) by approximately 7-fold. Similarly, erythromycin (a macrolide antibiotic) produced approximately a 2-fold increase in ebastine AUC. These substantial increases in plasma concentrations of the parent compound are associated with measurable, dose-dependent prolongation of the QTc interval on the electrocardiogram, which can predispose to serious ventricular arrhythmias including torsades de pointes.
For this reason, concurrent use of Ebastine Viatris with ketoconazole, itraconazole, erythromycin, and other potent CYP3A4 inhibitors (including nefazodone, ritonavir, and nelfinavir) is contraindicated or should be avoided. If a patient already taking ebastine requires treatment with one of these drugs, ebastine should be temporarily discontinued for the duration of the interacting treatment. Alternative antihistamines that are not significantly metabolized by CYP3A4, such as cetirizine, levocetirizine, or fexofenadine, can be substituted during this period.
Minor Interactions
At the recommended therapeutic dose of 10 mg, ebastine has not demonstrated clinically significant interactions with a number of commonly used medications. Specifically, clinical studies have shown that ebastine 10 mg does not significantly potentiate the CNS depressant effects of diazepam (a benzodiazepine) or alcohol when administered at the standard dose. However, it is prudent to exercise caution when combining ebastine with CNS depressants, particularly in patients who may be more sensitive to sedative effects.
Food does not significantly affect the overall bioavailability of ebastine, although high-fat meals may slightly increase the rate of absorption. The orodispersible tablet can therefore be taken with or without food. However, as noted above, large quantities of grapefruit juice should be avoided due to its inhibitory effect on intestinal CYP3A4.
If you are prescribed a new medication while taking Ebastine Viatris, always inform your doctor or pharmacist that you are taking an antihistamine metabolized by CYP3A4. This is particularly important when starting any new antifungal, antibiotic, or antiviral medication. Your healthcare provider can check for potential interactions and, if necessary, recommend a temporary switch to an alternative antihistamine.
What Is the Correct Dosage of Ebastine Viatris?
Always use Ebastine Viatris exactly as your doctor or pharmacist has instructed. The dosing recommendations are based on clinical pharmacokinetic and pharmacodynamic studies that have established the optimal balance between efficacy and safety for different patient populations.
Adults and Adolescents (12 years and older)
Standard Dosing
The recommended dose is 10 mg (one orodispersible tablet) once daily. The tablet should be placed on the tongue and allowed to dissolve without the need for water. However, water may be taken afterwards if desired. The tablet can be taken at any time of day, with or without food. For optimal symptom control, it is advisable to take the medication at approximately the same time each day.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults | 10 mg | Once daily | Place on tongue; no water needed |
| Adolescents (12–17 years) | 10 mg | Once daily | Same as adult dose |
| Children (<12 years) | Not recommended | – | Use age-appropriate alternatives |
| Elderly | 10 mg | Once daily | No dose adjustment; assess comorbidities |
| Mild–moderate hepatic impairment | 10 mg | Once daily | Use with caution; medical monitoring |
| Severe hepatic impairment | Contraindicated | – | Do not use; choose alternative |
Elderly Patients
No dose adjustment is necessary in elderly patients based on pharmacokinetic data. Studies in elderly healthy volunteers have shown that the pharmacokinetic profile of carebastine (the active metabolite) is not significantly different from that in younger adults. However, as elderly patients are more likely to have concomitant hepatic, renal, or cardiac disease and may be taking multiple medications, prescribers should assess the overall clinical picture carefully. In particular, the potential for QT prolongation should be considered in elderly patients with cardiovascular comorbidities or those taking other medications that affect the QT interval.
Missed Dose
If you forget to take a dose of Ebastine Viatris, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten dose. If you frequently forget to take your medication, consider setting a daily reminder or taking it at a consistent time each day (for example, every morning with breakfast or every evening before bed).
Overdose
If you suspect you or someone else has taken an overdose of Ebastine Viatris, seek immediate medical attention or contact your local poison control center. Symptoms of overdose may include headache, dizziness, dry mouth, nausea, and potentially cardiac rhythm disturbances (QT prolongation, tachycardia). There is no specific antidote for ebastine overdose; treatment is supportive and symptomatic, with ECG monitoring recommended.
In clinical trials and post-marketing surveillance, ebastine has demonstrated a wide therapeutic margin. However, at supratherapeutic doses (particularly above 40–60 mg), dose-dependent QT prolongation has been observed. In the event of an overdose, general supportive measures should be implemented, including monitoring of cardiac function (ECG), vital signs, and electrolytes. Gastric lavage or administration of activated charcoal may be considered if the overdose is recent (within 1–2 hours of ingestion). Hemodialysis is unlikely to be effective in removing ebastine or carebastine from the circulation due to their high protein binding (approximately 95%).
Remove the tablet from the blister pack with dry hands. Place the tablet on your tongue and allow it to dissolve – this typically takes only a few seconds. The dissolved medication is then swallowed with saliva. Do not crush, chew, or swallow the tablet whole. You may drink water after the tablet has dissolved if you wish, but it is not necessary. The orodispersible tablet should not be pushed through the blister foil; instead, peel back the foil to remove the tablet intact.
What Are the Side Effects of Ebastine Viatris?
Like all medicines, Ebastine Viatris can cause side effects, although not everybody gets them. The safety profile of ebastine has been well characterized through extensive clinical trial programs and decades of post-marketing surveillance worldwide. At the recommended dose of 10 mg once daily, ebastine is generally well tolerated with a side effect profile comparable to placebo in many clinical studies.
The following side effects have been reported with ebastine use. They are organized by frequency according to the standard classification system used by regulatory agencies:
Common
- Headache
- Dry mouth (xerostomia)
Uncommon
- Somnolence (drowsiness, sleepiness)
- Dizziness
- Nausea
- Abdominal pain
- Dyspepsia (indigestion)
- Insomnia (difficulty sleeping)
- Rhinitis (nasal inflammation)
- Sinusitis
- Fatigue
- Epistaxis (nosebleed)
Rare
- Palpitations
- Tachycardia (fast heartbeat)
- QT prolongation on ECG
- Urticaria (hives – as a paradoxical reaction)
- Skin rash
- Angioedema (deep tissue swelling)
- Elevated liver enzymes
Not Known
- Anaphylaxis (severe allergic reaction)
- Hepatitis
- Menstrual disturbances
- Arthralgia (joint pain)
- Myalgia (muscle pain)
It is important to note that the incidence of somnolence (drowsiness) with ebastine 10 mg in clinical trials was comparable to placebo and significantly lower than that observed with first-generation antihistamines. This non-sedating profile is a key advantage of second-generation antihistamines for patients who need to remain alert during the day, drive vehicles, or operate machinery.
The cardiac effects of ebastine have been thoroughly studied. At the recommended dose of 10 mg, no clinically significant QTc prolongation has been observed in healthy volunteers or in patients with allergic rhinitis or urticaria. However, at supratherapeutic doses (30 mg and above) or when ebastine is co-administered with potent CYP3A4 inhibitors, dose-dependent QTc prolongation can occur. A thorough QT study (TQT study) conducted in accordance with ICH E14 guidelines confirmed that ebastine 10 mg does not prolong the QTc interval to a clinically relevant degree, while ebastine 100 mg (a clear supratherapeutic dose used for assay sensitivity) produced measurable QTc prolongation.
Long-term safety data from clinical trials lasting up to 12 months and from extensive post-marketing surveillance have not identified any new safety signals or evidence of cumulative toxicity with prolonged ebastine use at the recommended dose. The benefit-risk balance of ebastine 10 mg for the approved indications is considered favorable by regulatory authorities including the European Medicines Agency (EMA).
Stop taking Ebastine Viatris and seek immediate medical help if you experience: signs of a severe allergic reaction (difficulty breathing, swelling of face, lips, tongue or throat, severe skin rash); palpitations, irregular heartbeat, or fainting (which may indicate cardiac rhythm disturbance); or severe abdominal pain with yellowing of the skin or eyes (which may indicate liver problems).
How Should You Store Ebastine Viatris?
Proper storage of Ebastine Viatris is essential to maintain the quality, efficacy, and safety of the medication throughout its shelf life. Orodispersible tablets are particularly sensitive to moisture because they are designed to disintegrate rapidly when exposed to liquid, so special care must be taken to protect them from humidity.
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze the tablets. Brief exposure to temperatures up to 30°C during transport is generally acceptable, but prolonged storage at elevated temperatures should be avoided.
- Moisture protection: Keep the tablets in the original blister packaging until immediately before use. The blister foil provides a moisture barrier that protects the orodispersible tablets from humidity. Do not transfer tablets to pill boxes or other containers that may not provide adequate moisture protection.
- Light protection: Store the blister packaging in the original outer carton to protect from light.
- Child safety: Keep this medicine out of the sight and reach of children. The orodispersible tablets may look like candy to young children, so store them securely.
- Expiry date: Do not use this medicine after the expiry date stated on the carton and blister (EXP). The expiry date refers to the last day of that month.
Do not flush unused medicines down the toilet or pour them down the drain. Return unused or expired Ebastine Viatris tablets to your local pharmacy or use a designated medicine disposal service. Proper medication disposal helps protect the environment and prevents accidental ingestion by children, pets, or other individuals.
What Does Ebastine Viatris Contain?
Active Ingredient
Each Ebastine Viatris orodispersible tablet contains 10 mg of ebastine as the active pharmaceutical ingredient. Ebastine (chemical name: 4-(4-benzhydryloxy-1-piperidyl)-1-(4-tert-butylphenyl)butan-1-one) has the molecular formula C32H39NO2 and a molecular weight of 469.66 g/mol. It is a white to off-white crystalline powder that is practically insoluble in water but soluble in organic solvents.
Excipients (Inactive Ingredients)
The orodispersible tablet formulation typically contains the following excipients, which serve various pharmaceutical functions:
- Gelatin: Used as a matrix former in the lyophilization process to create the rapidly disintegrating tablet structure.
- Mannitol: A sugar alcohol that acts as a filler, bulking agent, and contributes to the rapid disintegration and pleasant mouthfeel of the tablet.
- Aspartame (E951): An artificial sweetener that provides a pleasant taste to the orodispersible tablet. Contains a source of phenylalanine, which is relevant for patients with phenylketonuria (PKU).
- Citric acid: Used as a flavor enhancer and pH modifier to contribute to the taste profile of the tablet.
- Flavoring agents: Added to mask any unpleasant taste of the active ingredient and to improve patient acceptance of the orodispersible formulation.
This medicine contains aspartame, a source of phenylalanine. Aspartame is converted to phenylalanine upon ingestion. This may be harmful for patients with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine cannot be properly metabolized. If you have PKU, discuss this with your doctor before taking Ebastine Viatris.
The appearance of Ebastine Viatris orodispersible tablets is typically a white to off-white, round, flat, lyophilized wafer. Each tablet is individually sealed in a blister pack designed to protect it from moisture. The packaging includes detailed information about the product, including the batch number and expiry date.
Frequently Asked Questions About Ebastine Viatris
Ebastine, cetirizine, and loratadine are all second-generation (non-sedating) antihistamines used to treat allergic rhinitis and urticaria. The key differences lie in their pharmacokinetic profiles. Ebastine is a prodrug that requires hepatic metabolism by CYP3A4 to its active form (carebastine), which makes it susceptible to drug interactions with CYP3A4 inhibitors. Cetirizine is the active metabolite of hydroxyzine and is excreted largely unchanged through the kidneys, meaning it has fewer drug interactions but may cause slightly more drowsiness. Loratadine is also a prodrug (metabolized to desloratadine) but is generally considered to have fewer clinically significant CYP3A4 interactions. All three are effective for allergy relief, and the choice often depends on individual patient factors, concurrent medications, and local availability.
Yes, ebastine can be taken for extended periods when needed, such as for the duration of a pollen season (seasonal allergic rhinitis) or on an ongoing basis for perennial allergic rhinitis or chronic urticaria. Clinical trials lasting up to 12 months have demonstrated continued efficacy and a consistent safety profile with long-term use at the recommended dose of 10 mg daily. There is no evidence of tolerance (loss of effectiveness) developing with prolonged use. However, it is advisable to have regular check-ups with your doctor to review whether continued treatment is necessary and to monitor for any emerging issues.
Ebastine Viatris begins to provide symptom relief within approximately 1 to 3 hours after taking the orodispersible tablet. Peak plasma concentrations of the active metabolite carebastine are reached in about 2.6 to 4 hours after oral administration. The antihistaminic effect persists for at least 24 hours, supporting once-daily dosing. For seasonal allergy sufferers, some doctors recommend starting treatment a few days before the expected onset of the pollen season for optimal symptom control from the beginning of exposure.
Yes, Ebastine Viatris can be taken with or without food. Food does not significantly affect the overall bioavailability (total absorption) of ebastine, although a high-fat meal may slightly increase the rate of absorption. The orodispersible tablet dissolves on the tongue and does not need to be swallowed with food or water. You can take it at any time of day that is convenient for you, but taking it at a consistent time each day helps maintain steady drug levels and optimal symptom control.
Pharmacokinetic studies in elderly healthy volunteers have not shown clinically significant differences compared with younger adults, and no dose adjustment is required based on age alone. However, elderly patients are more likely to have concurrent medical conditions (hepatic impairment, cardiac disease) and to be taking multiple medications, which increases the potential for drug interactions. The prescribing physician should carefully assess the overall clinical picture, including cardiac risk factors and concurrent medications, before initiating ebastine therapy in elderly patients. If appropriate, ebastine 10 mg once daily is the standard dose for this age group.
If your allergy or urticaria symptoms are not adequately controlled with Ebastine Viatris 10 mg once daily, consult your doctor. Depending on your condition, your doctor may consider increasing the dose (up-dosing of second-generation antihistamines up to four times the standard dose is recommended by international urticaria guidelines for refractory chronic urticaria), switching to an alternative antihistamine, or adding complementary treatments. For allergic rhinitis, intranasal corticosteroid sprays, leukotriene receptor antagonists, or allergen immunotherapy may be considered. For chronic urticaria that does not respond to antihistamine up-dosing, omalizumab (an anti-IgE monoclonal antibody) or ciclosporin may be options. Do not increase the dose on your own without medical guidance.
References
- European Medicines Agency (EMA). Ebastine – Summary of Product Characteristics. Viatris. Last updated 2025.
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with WHO, GA2LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160. doi:10.1111/j.1398-9995.2007.01620.x.
- Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi:10.1111/all.15090.
- Rico S, Antonijoan RM, Barbanoj MJ. Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines. J Asthma Allergy. 2009;2:73–92.
- Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy. 2008;63 Suppl 89:1–20. doi:10.1111/j.1398-9995.2008.01897.x.
- Moss AJ, Chaikin P, Garcia JD, et al. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy. 1999;29 Suppl 3:200–205.
- World Health Organization (WHO). Allergic Rhinitis. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. 2007.
- British National Formulary (BNF). Antihistamines – non-sedating. National Institute for Health and Care Excellence (NICE). 2025.
- Church MK, Maurer M, Simons FER, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65(4):459–466. doi:10.1111/j.1398-9995.2009.02325.x.
- Antonijoan RM, Garcia-Gea C, Puntes M, et al. Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults. Clin Ther. 2007;29(5):814–822.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in allergy, immunology, and clinical pharmacology with extensive experience in antihistamine therapy, allergic rhinitis management, and urticaria treatment.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, EAACI, ARIA, BNF).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.